Walleye Capital’s Clarus Therapeutics Holdings, Inc. Warrants CRXTW Stock Holding History

Walleye Capital’s Portfolio CRXTW Stock Details CRXTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-21,811	Closed	-$2K	–	3725
2022 Q2	$2K	Buy	21,811 +8,863	+68%	+$872	﹤0.01%	2288
2022 Q1	$2K	Hold	12,948	–	–	﹤0.01%	2247
2021 Q4	$4K	Sell	12,948 -20,000	-61%	-$10.2K	﹤0.01%	2066
2021 Q3	$25K	Sell	32,948 -12,052	-27%	-$9.09K	﹤0.01%	1468
2021 Q2	$34K	Buy	+45,000	New	+$28.2K	﹤0.01%	1264

Other funds holding CRXTW

MSU

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

Walleye Capital's CRXTW Position: Q3 2022 in Review

Walleye Capital sold out of Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) in Q3 2022, closing a stake of 21,811 shares — an estimated $2K sold.

Walleye Capital first reported a position in CRXTW in Q2 2021 and held it in 5 quarters. The position peaked at $34K in Q2 2021. 5 funds tracked by Wall St. Rank hold CRXTW as of Q3 2022.

Walleye Capital reported no remaining Clarus Therapeutics Holdings, Inc. Warrants position as of Q3 2022 after selling out during the quarter.
Walleye Capital sold 21,811 Clarus Therapeutics Holdings, Inc. Warrants shares in Q3 2022, an estimated $2K.
Walleye Capital first reported a position in Clarus Therapeutics Holdings, Inc. Warrants in Q2 2021 and held it in 5 quarters.
Walleye Capital's Clarus Therapeutics Holdings, Inc. Warrants position peaked at $34K in Q2 2021.
5 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Warrants as of Q3 2022.

Based on Walleye Capital's 13F filing for Q3 2022, filed 14 Nov 2022.